Sick leave duration as a potential marker of functionality and disease severity in depression

Objective: To discuss the impact of depression on work and how depression-related sick leave duration could be a potential indicator and outcome for measuring functionality in depression.Methods: Our review was based on a literature search and expert opinion that emerged during a virtual meeting of European psychiatrists that was convened to discuss this topic.Results: Current evidence demonstrates that depression-related sick leave duration is influenced by multiple disease-, patient- and work-related factors, together with societal attitudes towards depression and socioeconomic conditions. A wide variety of pharmacological and non-pharmacological treatments and work-based interventions are effective in reducing depression-related sick leave duration and/or facilitating return to work. Recent real-world evidence showed that patients treated with antidepressant monotherapy appear to recover their working life faster than those receiving combination therapy. Although depression-related sick leave duration was found to correlate with severity of depressive symptoms, it cannot be used alone as a viable marker for disease severity.Conclusions: Given its multifactorial nature, depression-related sick leave duration is not on its own a viable outcome measure of depression severity but could be used as a secondary outcome alongside more formal severity measures and may also represent a useful measure of functionality in depression. Key pointsDepression in the working population and depression-related sick leave have a profound economic impact on societyDepression-related sick leave duration is influenced by multiple disease-, patient- and work-related factors, together with societal attitudes towards depression and socioeconomic conditionsA wide variety of pharmacological and non-pharmacological treatments and work-based interventions have been shown to be effective in reducing depression-related sick leave duration and/or facilitating return to workIn terms of pharmacological intervention, recent real-world evidence has shown that patients treated with antidepressant monotherapy are able to recover their working life faster than those treated with combination therapyAlthough depression-related sick leave duration has been shown to correlate with severity of depressive symptoms, it is not a viable outcome measure of depression severity on its own, but could be used as secondary outcome alongside more formal clinician- and patient-rated severity measuresDepression-related sick leave duration may, however, represent a viable outcome for measuring functionality in depression.

Medienart:	E-Artikel

Erscheinungsjahr:	2022
Erschienen:	2022

Enthalten in:	Zur Gesamtaufnahme - volume:26
Enthalten in:	International journal of psychiatry in clinical practice - 26(2022), 4 vom: 04. Nov., Seite 406-416

Sprache:	Englisch

Beteiligte Personen:

Volz, Hans-Peter [VerfasserIn] Bartečků, Elis [VerfasserIn] Bartova, Lucie [VerfasserIn] Bessa, João [VerfasserIn] De Berardis, Domenico [VerfasserIn] Dragasek, Jozef [VerfasserIn] Kozhuharov, Hristo [VerfasserIn] Ladea, Maria [VerfasserIn] Lazáry, Judit [VerfasserIn] Roca, Miquel [VerfasserIn] Usov, Grigory [VerfasserIn] Wichniak, Adam [VerfasserIn] Godman, Brian [VerfasserIn] Kasper, Siegfried [VerfasserIn]

Links:	Volltext

Themen:	Absenteeism Antidepressive Agents Depression Functionality Journal Article Major depressive disorder Return to work Review Sick leave

Anmerkungen:	Date Completed 07.12.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE

doi:	10.1080/13651501.2022.2054350

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	NLM339035625